摘要
2021年淋巴瘤的治疗新药、新方法层出不穷,治疗策略也不断推陈出新。以CD20×CD3为代表的双抗类药物治疗复发/难治性弥漫大B细胞淋巴瘤的总有效率超过60%。以polatuzumab vedotin和loncastuximab tesirine为代表的抗体药物偶联物的总有效率也可达到40%左右。免疫检查点抑制剂在复发/难治性霍奇金淋巴瘤和NK/T细胞淋巴瘤治疗方面也取得了不错的疗效。以维奈克拉和布鲁顿酪氨酸激酶抑制剂为代表的小分子药物也改写了套细胞淋巴瘤和慢性淋巴细胞白血病的治疗策略。嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)治疗的出现使得自体造血干细胞移植的地位受到了挑战。
More and more new drugs and treatment strategies for lymphoma emerged in 2021.Bispecific antibody targeted on CD20×CD3 resulted in an overall response rate of more than 60% when it was used for relapsed/refractory diffuse large B-cell lymphoma.Antibody-drug conjugate such as polatuzumab vedotin and loncastuximab tesirine also led to an overall response rate of about 40%.Immune checkpoint inhibitors showed a good efficacy in the treatment of relapsed/refractory Hodgkin lymphoma and NK/T cell lymphoma.Small molecule drugs such as venetoclax and Bruton’s tyrosine kinase inhibitors changed treatment strategies for mantle cell lymphoma and chronic lymphocytic leukemia.The emergence of chimeric antigen receptor T cells (CAR-T) therapy made us reevaluate the role of autologous hematopoietic stem cell transplantation.
作者
刘卫平
朱军
Liu Weiping;Zhu Jun(Department of Lymphoma,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)
出处
《肿瘤综合治疗电子杂志》
2022年第1期94-98,共5页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家自然科学基金面上项目(82070205)。
关键词
淋巴瘤
免疫治疗
靶向治疗
细胞治疗
Lymphoma
Immunotherapy
Targeted therapy
Cell therapy
